For decades, Eisai has led the way in dementia research and development. Now we’re broadening our scope, taking a multi-dimensional, targeted path to our ultimate goal: prevention and a cure. Here’s a quick look at what we’re working on right now.

Blood Test for Alzheimer


We’re collaborating with Sysmex on a potential blood-based test for predicting amyloid pathology. This automated immune-assay system under investigation could also be utilized as a simpler and more cost-effective method to identify participants for clinical trials exploring a variety of AD therapies now in development.

Alzheimer’s disease: global impact, pathophysiology, and the evolving clinical care

Alzheimer’s disease is a growing global health challenge and has an enormous impact on patients and family members, healthcare systems and society at large. In the three videos below, Dr. Harald Hampel, Vice President and Chief Medical Officer of the Neurology Business Group, and a global expert in Alzheimer’s Disease discusses the global impact of dementia due to Alzheimer’s and other neurodegenerative diseases. In addition, he presents existing multi-disciplinary evidence that supports the role of the amyloid-β pathway in Alzheimer’s disease pathophysiology and therapy development. Finally, he provides future perspectives on Alzheimer’s disease research and clinical care.

Learn from leading AD experts about the A/T/N system and how it may shape clinical practice and therapy development

Discover the A/T/N system – a biomarker-based classification system that classifies individuals using core AD pathophysiological features: amyloid-β(A), tau (T) and neurodegeneration (N). Presented at the 2020 Alzheimer’s Association International Conference (AAIC), the three presentations provide a state-of-the-art overview on the validation and qualification of the A/T/N system and its evolution to A/T/N/x for AD clinical practice and therapy development.

“The A/T/N system offers a framework to define Alzheimer’s disease in a continuum using biologically rooted measurements. It circumvents the limitations of the traditional, clinical phenotype-based approach, and has the potential to facilitate therapeutic interventions at the early stages of the disease.”

Harald Hampel
Chief Medical Officer
Neurology Business Group